A Reversal for MEDIGENE AG (OTCMKTS:MDGEF) Is Not Near. The Stock Has Rise in Shorts

February 15, 2018 - By marketbeat

The stock of MEDIGENE AG (OTCMKTS:MDGEF) registered an increase of 0.22% in short interest. MDGEF’s total short interest was 89,500 shares in February as published by FINRA. Its up 0.22% from 89,300 shares, reported previously.

It closed at $19.05 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. The company has market cap of $442.42 million. It operates through two divisions, Immunotherapies and Other Products. It currently has negative earnings. The firm develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.

More notable recent Medigene AG (OTCMKTS:MDGEF) news were published by: Businesswire.com which released: “bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance …” on September 29, 2016, also Globenewswire.com with their article: “Medigene AG to be included in TecDAX Index” published on December 06, 2016, Seekingalpha.com published: “Medigene Keeps Eyes On Immunotherapy Prize” on December 22, 2015. More interesting news about Medigene AG (OTCMKTS:MDGEF) were released by: Globenewswire.com and their article: “Medigene appoints Dr. Thomas Taapken as Chief Financial Officer” published on November 22, 2016 as well as Seekingalpha.com‘s news article titled: “Medigene AG: Addressing The CAR-T Market Pain Points” with publication date: March 18, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: